Versor Investments LP Takes $47.04 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Versor Investments LP Takes $47.04 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Versor Investments LP bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 625,067 shares of the company's stock, valued at approximately $47,036,000. Turning Point Therapeutics accounts for 1.8% of Versor Investments LP's portfolio, making the stock its 20th biggest position. Versor Investments LP owned 1.26% of Turning Point Therapeutics as of its most recent SEC filing.
根據Versor Investments LP在第二季度購買了Turning Point Treateutics，Inc.(納斯達克代碼：TPTX-GET Rating)的新股份，該公司在提交給美國證券交易委員會(SEC)的最新Form 13F文件中表示。該基金購買了625,067股該公司股票，價值約47,036,000美元。Turning Point Treateutics佔Versor Investments LP投資組合的1.8%，使該股成為其第20大頭寸。截至最近提交的美國證券交易委員會申請文件，Versor Investments LP持有Turning Point Treateutics 1.26%的股份。
Other institutional investors also recently modified their holdings of the company. State Street Corp raised its stake in Turning Point Therapeutics by 37.2% in the first quarter. State Street Corp now owns 3,119,926 shares of the company's stock valued at $83,770,000 after purchasing an additional 845,408 shares in the last quarter. Federated Hermes Inc. raised its stake in Turning Point Therapeutics by 19.7% in the first quarter. Federated Hermes Inc. now owns 2,075,037 shares of the company's stock valued at $55,715,000 after purchasing an additional 341,455 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in Turning Point Therapeutics by 69.1% in the second quarter. Frontier Capital Management Co. LLC now owns 195,959 shares of the company's stock valued at $14,746,000 after purchasing an additional 80,062 shares in the last quarter. Barclays PLC raised its stake in Turning Point Therapeutics by 352.3% in the fourth quarter. Barclays PLC now owns 92,085 shares of the company's stock valued at $4,393,000 after purchasing an additional 71,727 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Turning Point Therapeutics by 20.4% during the first quarter. JPMorgan Chase & Co. now owns 384,426 shares of the company's stock worth $10,323,000 after acquiring an additional 65,212 shares in the last quarter. Institutional investors own 90.33% of the company's stock.
其他機構投資者最近也調整了對該公司的持股。道富集團第一季度將其在Turning Point Treateutics的持股比例提高了37.2%。道富銀行目前持有該公司3,119,926股股票，價值83,770,000美元，此前該公司在上個季度又購買了845,408股。聯合愛馬仕公司在第一季度將其在Turning Point Treateutics的持股增加了19.7%。聯合愛馬仕公司目前持有該公司2,075,037股股票，價值55,715,000美元，上一季度又購買了341,455股。FronTier Capital Management Co.LLC在第二季度增持了69.1%的Turning Point Treeutics股份。FronTier Capital Management Co.LLC現在持有195,959股該公司股票，價值14,746,000美元，上一季度又購買了80,062股。巴克萊在第四季度將其在Turning Point Treateutics的持股比例提高了352.3%。巴克萊現在持有92,085股該公司股票，價值4,393,000美元，上個季度又購買了71,727股。最後，摩根大通在第一季度將其在Turning Point Treateutics的持股比例提高了20.4%。摩根大通在上個季度增持了65,212股，目前持有384,426股該公司股票，價值10,323,000美元。機構投資者持有該公司90.33%的股票。
Insider Activity at Turning Point Therapeutics
轉折點治療公司的內部活動
In related news, CFO Paolo Tombesi sold 1,183 shares of the company's stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total value of $88,654.02. Following the sale, the chief financial officer now directly owns 28,700 shares in the company, valued at $2,150,778. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by company insiders.
在相關新聞中，首席財務官保羅·湯貝西在7月27日星期三的一筆交易中出售了1,183股該公司股票。這隻股票的平均售價為74.94美元，總價值為88,654.02美元。出售後，這位首席財務官現在直接持有該公司28,700股票，價值2,150,778美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。8.60%的股份目前由公司內部人士持有。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Turning Point Therapeutics Price Performance
轉折點治療性價比
Shares of NASDAQ:TPTX remained flat at $76.01 during midday trading on Friday. The stock had a trading volume of 4,322 shares, compared to its average volume of 1,137,726. The firm has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. The business's 50 day simple moving average is $75.81 and its 200-day simple moving average is $59.18. Turning Point Therapeutics, Inc. has a 52 week low of $23.77 and a 52 week high of $82.20.
納斯達克：多倫多證券交易所的股價在週五午盤交易中持平於76.01美元。該股成交量為4322股，而其平均成交量為1137,726股。該公司市值為38.1億美元，市盈率為-11.02倍，貝塔係數為-0.18倍。該業務的50日簡單移動均線切入位在75.81美元，200日簡單移動均線切入位在59.18美元。Turning Point Treateutics，Inc.的52周低點為23.77美元，52周高點為82.20美元。
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last released its quarterly earnings results on Monday, August 8th. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.78) by ($0.70). The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $2.27 million. The company's revenue was down 97.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.14) EPS. Research analysts forecast that Turning Point Therapeutics, Inc. will post -7.69 earnings per share for the current fiscal year.
Turning Point Treateutics(納斯達克：多倫多證券交易所股票代碼：GET)最近一次發佈季度收益報告是在8月8日(星期一)。該公司公佈本季度每股收益(2.48美元)，低於(1.78美元)和(0.70美元)的普遍預期。該公司本季度營收為12萬美元，而市場普遍預期為227萬美元。該公司的收入同比下降了97.7%。在前一年的同一季度，該業務公佈了每股收益(1.14美元)。研究分析師預測，Turning Point Treateutics，Inc.本財年每股收益將達到7.69美元。
Turning Point Therapeutics Profile
轉折點治療簡介
(Get Rating)
(獲取評級)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治療公司是一家臨牀階段的精確腫瘤學生物製藥公司，致力於設計和開發針對癌症遺傳驅動因素的治療方法。它開發了一系列酪氨酸激酶抑制劑(TKI)，針對TKI-NAI、̈Ve和TKI預治療患者的癌症基因驅動因素。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- 2 Regional Banks With Sector-Beating Price Performance
- MarketBeat: Week in Review 10/3-10/7
- ConAgra Brands Is A Value Pick For Income Investors
- 3 Stocks With Market-Beating Price Performance
- Lucid Motors May Test Investors' Resolve, But Should They Sell?
- 免費獲取StockNews.com關於轉折點治療(TPTX)的研究報告
- 2家地區性銀行的價格表現優於行業
- MarketBeat：回顧一週10/3-10/7
- 康尼格拉品牌是收益投資者的價值選擇
- 3只股價表現優於大盤的股票
- Lucid Motors可能會考驗投資者的決心，但他們應該出售嗎？
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《轉折點治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Turning Point Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。